This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| GoodRx | |
|---|---|
| Name | GoodRx |
| Type | Public |
| Founded | 2011 |
| Founders | Doug Hirsch, Trevor Bezdek, Scott Marlette |
| Headquarters | Santa Monica, California, United States |
| Key people | Doug Hirsch (CEO) |
| Industry | Healthcare, Technology, Pharmacy benefit |
GoodRx GoodRx is an American technology company that operates a digital marketplace for prescription drugs, connecting consumers with price comparisons, discount coupons, and telehealth services. The company provides tools to compare medication prices across pharmacies, partners with pharmacy chains and pharmacy benefit managers, and offers telemedicine and lab testing services. GoodRx has been involved in debates over pharmaceutical pricing, transparency, and the role of intermediaries in the United States healthcare system.
GoodRx was founded in 2011 by Doug Hirsch, Trevor Bezdek, and Scott Marlette in Santa Monica, California, during a period of rising attention to pharmaceutical pricing highlighted by events such as the 2015 controversy over Daraprim pricing and broader reporting by outlets like The New York Times and ProPublica. Early seed funding drew on networks connected to Y Combinator and angel investors associated with Silicon Valley firms including Sequoia Capital and entrepreneurs active in startups such as Uber and Airbnb. As the company scaled, it raised venture capital in rounds involving investors related to Kleiner Perkins, Accel Partners, and later went public via an initial public offering on the NASDAQ stock exchange. GoodRx’s growth paralleled policy debates in the United States Senate and hearings by the House Committee on Oversight and Reform about drug prices and pharmacy benefit manager practices.
GoodRx operates a consumer-facing platform that aggregates pricing and coupon information, competing with services like SingleCare and pharmacy chains such as Walgreens Boots Alliance and CVS Health. The company’s core service uses negotiated rates from pharmacy benefit managers and direct contracts with chains such as Rite Aid and regional independents. Additional services expanded into telemedicine via acquisitions and partnerships with entities in telehealth ecosystems including Teladoc Health-adjacent startups and virtual care providers used by employers like Walmart and UnitedHealth Group. GoodRx also offers lab testing coordination and specialty drug price tools similar in function to services provided by Cigna and Humana ancillary programs. Revenue streams include fees from pharmacy benefit managers, payments from pharmaceutical manufacturers for coupon redemptions, and subscription services marketed to employers and consumers.
GoodRx’s platform leverages web scraping, application programming interfaces, and data aggregation techniques akin to systems built by large technology firms such as Google, Amazon, and Microsoft in cloud deployments on providers like Amazon Web Services and Google Cloud Platform. The company maintains databases of National Drug Codes and leverages standards promulgated by organizations like HL7 and references to coding systems used by the Centers for Medicare & Medicaid Services for drug pricing benchmarking. GoodRx collects user and pharmacy transaction data, employing analytics and machine learning approaches comparable to those used by IBM Watson Health and ad platforms from Facebook. Its privacy and data-use practices have been compared in congressional testimony to practices scrutinized in cases involving technology companies like Equifax and Cambridge Analytica.
GoodRx has been subject to regulatory and legal scrutiny involving pharmacy benefit managers, prescription rebates, and transparency rules administered by agencies including the Department of Justice and the Federal Trade Commission. Lawsuits have touched on allegations similar to those raised in actions against Express Scripts and CVS Caremark around rebate-driven incentives, and settlements in the sector have invoked statutes such as the Anti-Kickback Statute and state consumer protection laws enforced by attorneys general from states like California and New York (state). Financial reporting and disclosures during the IPO drew analyst attention from institutional investors including BlackRock and Vanguard Group, and the company faced market volatility similar to other healthcare tech IPOs like Zocdoc-adjacent firms and digital health companies listed on the NASDAQ.
GoodRx has been praised by consumer advocates, patient groups such as the American Diabetes Association and American Heart Association, and journalists at outlets like The Wall Street Journal for enabling immediate out-of-pocket savings for uninsured and underinsured patients. Critics among policy researchers affiliated with institutions like Kaiser Family Foundation and academic centers at Harvard Medical School and Stanford University have argued the platform can obscure underlying list prices and interacts with rebate models employed by Pfizer, Merck, and Johnson & Johnson. Health economists who have published in journals alongside researchers from Johns Hopkins University and Yale School of Medicine debate whether coupon-driven discounts reduce long-term system costs or shift burdens across payers and manufacturers.
GoodRx has pursued strategic acquisitions and partnerships with telehealth providers, pharmacy chains, and diagnostic firms; these moves mirror consolidation patterns seen with companies like McKesson and Cardinal Health. Notable deals connected GoodRx to telemedicine startups and laboratory services used by employers including Amazon and Google (company), and involved investors and advisors formerly affiliated with Warburg Pincus and Silver Lake Partners. Partnerships have also included collaborations with patient advocacy organizations and digital health platforms that interface with electronic health record vendors such as Epic Systems and Cerner Corporation.
GoodRx’s operations have been primarily concentrated in the United States market, with limited international pilots and comparative studies referencing drug pricing systems in countries such as Canada, United Kingdom, Australia, and EU member states including Germany and France. Cross-border comparisons invoke regulatory frameworks like those overseen by Health Canada and the European Medicines Agency and illustrate contrasts with single-payer and national health systems exemplified by National Health Service (England) and Medicare (Australia). International expansion efforts encountered challenges analogous to those faced by other US-based digital health firms entering markets regulated by agencies such as NHS England and national reimbursement authorities.
Category:Health care companies of the United States Category:Pharmacy services